Clinical Trials
3
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (33.3%)Phase 2
1 (33.3%)Phase 3
1 (33.3%)Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
Phase 3
Completed
- Conditions
- Kidney Transplant Recipient
- Interventions
- Biological: Janssen Ad26.CoV2.S VaccineOther: Reduction in Immunosuppression MedicationOther: Maintenance in Immunosuppression Medication
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Mark Stegall
- Target Recruit Count
- 468
- Registration Number
- NCT05220397
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Mark Stegall
- Target Recruit Count
- 4
- Registration Number
- NCT01349595
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Mark Stegall
- Target Recruit Count
- 31
- Registration Number
- NCT00670774
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
News
No news found